<span item_type="fundamental" item_id="bfab4f12800a707b0788c882ff9d1dd1" counter_id="ST/US/APRE" env="prod"></span><span item_type="announcement" item_id="647868015588999169" env="prod"></span><p>Revenue: As of FY2026 Q1, the actual value is USD 0, meeting the estimate of USD 0.</p><p>EPS: As of FY2026 Q1, the actual value is USD -0.22, beating the estimate of USD -0.23.</p><p>EBIT: As of FY2026 Q1, the actual value is USD -3.565 M.</p><p></p><h4>Cash and Cash Equivalents</h4><p>Aprea Therapeutics, Inc. reported cash and cash equivalents of $46.5 million as of March 31, 2026, an increase from $14.6 million as of December 31, 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1781983/000110465926059734/apre-20260513xex99d1.htm"></span>. The company had approximately $46.5 million in cash and equivalents as of March 31, 2026 <span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1781983/000110465926059734/apre-20260513xex99d2.htm"></span>.</p><h4>Operating Loss</h4><p>For the first quarter ended March 31, 2026, Aprea Therapeutics, Inc. reported an operating loss of - $3.4 million, which improved from an operating loss of - $4.1 million in the first quarter of 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1781983/000110465926059734/apre-20260513xex99d1.htm"></span>.</p><h4>Research and Development (R&amp;D) Expenses</h4><p>R&amp;D expenses for the first quarter ended March 31, 2026, were $1.6 million, down from $2.5 million for the comparable period in 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1781983/000110465926059734/apre-20260513xex99d1.htm"></span>. This decrease was primarily due to a - $0.8 million reduction related to the ABOYA-119 clinical trial <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1781983/000110465926059734/apre-20260513xex99d1.htm"></span>.</p><h4>General and Administrative (G&amp;A) Expenses</h4><p>G&amp;A expenses remained consistent at $1.8 million for both the first quarter of 2026 and 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1781983/000110465926059734/apre-20260513xex99d1.htm"></span>.</p><h4>Net Loss</h4><p>The net loss for the first quarter ended March 31, 2026, was - $3.3 million, an improvement compared to a net loss of - $3.9 million for the same period in 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1781983/000110465926059734/apre-20260513xex99d1.htm"></span>.</p><h4>Net Loss Per Share</h4><p>Net loss per basic share was - $0.22 for the first quarter of 2026, compared to - $0.66 per basic share in the first quarter of 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1781983/000110465926059734/apre-20260513xex99d1.htm"></span>.</p><h4>Grant Revenue</h4><p>Grant revenue was $0 for the first quarter of 2026, down from $162,463 in the first quarter of 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1781983/000110465926059734/apre-20260513xex99d1.htm"></span>.</p><h4>Other Income</h4><p>Interest income, net, was $134,784 for Q1 2026, compared to $204,726 for Q1 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1781983/000110465926059734/apre-20260513xex99d1.htm"></span>. Foreign currency gain was $7,711 for Q1 2026, shifting from a loss of - $51,803 in Q1 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1781983/000110465926059734/apre-20260513xex99d1.htm"></span>.</p><h4>Gross Proceeds from Private Placement</h4><p>Aprea Therapeutics, Inc. closed an oversubscribed $30 million private placement on March 31, 2026, with proceeds intended to support the development of APR-1051 and general corporate purposes <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1781983/000110465926059734/apre-20260513xex99d1.htm"></span>. Aprea Therapeutics, Inc. raised $30.0 million in gross proceeds from a private placement that closed on March 31, 2026 <span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1781983/000110465926059734/apre-20260513xex99d2.htm"></span>.</p><h4>Operational Highlights</h4><p>The ACESOT-1051 trial of WEE1 inhibitor APR-1051 observed two partial responses, with one confirmed at a second imaging assessment <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1781983/000110465926059734/apre-20260513xex99d1.htm"></span>. Dose escalation is ongoing in the 300 mg cohort for ACESOT-1051, with plans to expand enrollment to include at least 50 patients with uterine serous carcinoma and cyclin E-overexpressing, platinum-resistant ovarian cancer <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1781983/000110465926059734/apre-20260513xex99d1.htm"></span>. The ABOYA-119 clinical trial for ATRN-119 was strategically paused for monotherapy, and the company is exploring combination approaches and potential investigator-led studies <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1781983/000110465926059734/apre-20260513xex99d1.htm"></span>. In February 2026, Dr. Eugene Kennedy was appointed as Chief Medical Advisor <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1781983/000110465926059734/apre-20260513xex99d1.htm"></span>.</p><h4>Securities Common Equivalents (as of May 13, 2026)</h4><p>Preferred Stock (as converted) totaled 15,596, Common Stock was 12,382,776, Warrants amounted to 89,638,517, Options were 1,050,501, and Restricted Stock Units were 48,718 <span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1781983/000110465926059734/apre-20260513xex99d2.htm"></span>. The fully diluted equivalents totaled 103,120,512 <span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1781983/000110465926059734/apre-20260513xex99d2.htm"></span>.</p><h4>Outlook / Guidance</h4><p>Aprea Therapeutics, Inc. anticipates that its cash and cash equivalents of $46.5 million as of March 31, 2026, will be sufficient to meet projected operating expenses and capital expenditure requirements into the first quarter of 2028 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1781983/000110465926059734/apre-20260513xex99d1.htm"></span><span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1781983/000110465926059734/apre-20260513xex99d2.htm"></span>. Additional clinical data from ACESOT-1051 is expected to be presented at the ASCO 2026 Annual Meeting on May 30, 2026, with completion of dose escalation anticipated in the second quarter of 2027 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1781983/000110465926059734/apre-20260513xex99d1.htm"></span><span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1781983/000110465926059734/apre-20260513xex99d2.htm"></span>. For ATRN-119, the recommended Phase 2 dose (RP2D) was determined in October 2025, and potential collaborations on combinations are expected in the second half of 2026 <span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1781983/000110465926059734/apre-20260513xex99d2.htm"></span>.</p>

Aprea Therapeutics | 8-K: FY2026 Q1 Revenue Meets Estimate at USD 0